Loading…
Reported covered position: Deputy Health Policy Director, Senate Committee on Health, Education, Labor and Pensions; Deputy Press Secretary, Office of Senator Lamar Alexander
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Restore Protections for Dialysis Patients Act
Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare policies impacting ESRD; Restore Protections for Dialysis Patients Act - H.R.2199/S.1173; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis; Kidney Care Access Protection Act - H.R. 6214/S.2730
Restore Protections for Dialysis Patients Act
Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ARGENTA US HOLDINGS, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to animal health
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FLOREO INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Source: Senate LDA
| AVALON HEALTHCARE SOLUTIONS |
| 6 |
| 2025–2026 |
| BIOTISSUE | 6 | 2025–2026 |
| BOEHRINGER INGELHEIM PHARMACEUTICALS INC | 6 | 2025–2026 |
| BROOKDALE SENIOR LIVING INC. | 6 | 2025–2026 |
| CATALYST PHARMACEUTICALS | 6 | 2025–2026 |
| COLLEGIUM PHARMACEUTICAL | 6 | 2025–2026 |
| GENUS LIFESCIENCES | 6 | 2025–2026 |
| GILEAD SCIENCES, INC. | 6 | 2025–2026 |
| GLAUKOS CORPORATION (FKA AVEDRO, INC.) | 6 | 2025–2026 |
| HARMONY BIOSCIENCES, LLC | 6 | 2025–2026 |
| HARROW INC. | 6 | 2025–2026 |
| ILLUMINA, INC. | 6 | 2025–2026 |
| INNOVAGE | 6 | 2025–2026 |
| INSMED, INC. | 6 | 2025–2026 |
| KENDAL NUTRICARE LTD | 6 | 2025–2026 |
| LIVANOVA USA INC | 6 | 2025–2026 |
| MEDICAL DEVICE MANUFACTURERS ASSOCIATION | 6 | 2025–2026 |
| MICROTRANSPONDER | 6 | 2025–2026 |
| MOMENTOUS | 6 | 2025–2026 |
| NEUROTECH PHARMACEUTICALS | 6 | 2025–2026 |
| ONE CALL, CORP | 6 | 2025–2026 |
| ORGANON & CO. | 6 | 2025–2026 |
| PHARMING HEALTHCARE, INC. | 6 | 2025–2026 |
| PHATHOM PHARMACEUTICALS | 6 | 2025–2026 |
| RECOR MEDICAL | 6 | 2025–2026 |
| SPARC | 6 | 2025–2026 |
| SSI GROUP | 6 | 2025–2026 |
| STERIS CORPORATION | 6 | 2025–2026 |
| SUMMIT BEHAVIORAL HEALTHCARE | 6 | 2025–2026 |
| SUPERNUS PHARMACEUTICALS, INC. | 6 | 2025–2026 |
| TENNESSEE RURAL HEALTH IMPROVEMENT ASSOCIATION (FKN TENNESSEE FARM BR. ASSN.) | 6 | 2025–2026 |
| TERUMO BCT | 6 | 2025–2026 |
| THE ALLERGY & ASTHMA ALLIANCE | 6 | 2025–2026 |
| U.S. RENAL CARE | 6 | 2025–2026 |
| WE WORK FOR HEALTH | 6 | 2025–2026 |
| ACME UNITED CORPORATION | 5 | 2025–2026 |
| ALEXION PHARMACEUTICALS | 5 | 2025–2026 |
| Agios Pharmaceuticals, Inc. | 5 | 2025–2026 |
| JCYTE, INC. | 5 | 2025–2026 |
| PAR HEALTH USA, LLC | 5 | 2025–2026 |
| THE ALLERGY, ASTHMA & SINUS CENTER | 5 | 2025–2026 |
| AVITA MEDICAL, INC. | 4 | 2025–2026 |
| AXOGEN CORPORATION | 4 | 2025–2026 |
| BIOGEN INC. | 4 | 2025 |
| COLOPLAST CORP | 4 | 2026 |
| GENETIX BIOTHERAPEUTICS | 4 | 2025–2026 |
| HEART FAILURE ADVOCATES OF AMERICA LLC | 4 | 2025 |
| INDIVIOR INC. | 4 | 2025–2026 |
| NEUSPERA MEDICAL | 4 | 2025–2026 |
| ORCHARD THERAPEUTICS NORTH AMERICA | 4 | 2026 |
| Opus Genetics, Inc. | 4 | 2025–2026 |
| RAYNER INTRAOCULAR LENSES LIMITED | 4 | 2026 |
| SI-BONE, INC. | 4 | 2025 |
| SKY MARKETING CORPORATION | 4 | 2026 |
| scPharmaceuticals Inc. | 4 | 2025–2026 |
| ATARA BIOTHERAPEUTICS, INC. | 3 | 2026 |
| CIDR | 3 | 2025 |
| CLEARFLOW, INC. | 3 | 2026 |
| COALITION FOR AFFORDABLE PET CARE | 3 | 2026 |
| CUBBY BEDS | 3 | 2025–2026 |
| ENDO USA, INC., A MALLINCKRODT-ENDO COMPANY | 3 | 2025 |
| GALVANIZE THERAPEUTICS, INC. | 3 | 2025–2026 |
| GAURDANT HEALTH | 3 | 2026 |
| HR HEALTHCARE | 3 | 2025 |
| INDEMED | 3 | 2026 |
| INTRINSIC THERAPEUTICS | 3 | 2025 |
| MAGNOLIA MEDICAL TECHNOLOGIES, INC. | 3 | 2026 |
| MAGNUS MEDICAL, INC. | 3 | 2026 |
| MANNKIND CORPORATION | 3 | 2026 |
| NEURALINK CORP. | 3 | 2026 |
| NOVAVAX | 3 | 2025 |
| ARCUTIS BIOTHERAPEUTICS, INC. | 2 | 2026 |
| ARGENTA US HOLDINGS, INC. | 2 | 2026 |
| CARA MEDICAL | 2 | 2026 |
| FLEX VASCULAR | 2 | 2026 |
| FLOREO INC. | 2 | 2026 |
| GOSSAMER BIO, INC. | 2 | 2026 |
| HCA MANAGEMENT SERVICES, L.P. | 2 | 2026 |
| HISTOSONICS, INC | 2 | 2026 |
| PROVERUM MEDICAL | 2 | 2026 |
| ARTERA INC. | 1 | 2026 |
| HANSA BIOPHARMA AB | 1 | 2026 |
| IBA PROTON THERAPY | 1 | 2026 |
| MEDICARE ALLIANCE FOR BENEFICIARY ACCESS, INC. | 1 | 2025 |
Issues related to Medicare policies impacting ESRD; Restore Protections for Dialysis Patients Act - H.R.2199/S.1173; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis; Kidney Care Access Protection Act - H.R. 6214/S.2730
Restore Protections for Dialysis Patients Act
Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare policies impacting ESRD; Restore Protections for Dialysis Patients Act - H.R.2199/S.1173; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis; Kidney Care Access Protection Act - H.R. 6214/S.2730
Early Detection of Vision Impairments for Children Act of 2025
Client: GLAUKOS CORPORATION (FKA AVEDRO, INC.) · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
H.R. 2527, the Early Detection of Vision Impairments for Children Act
Early Detection of Vision Impairments for Children Act of 2025
Client: GLAUKOS CORPORATION (FKA AVEDRO, INC.) · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
H.R. 2527, the Early Detection of Vision Impairments for Children Act
Kidney Care Access Protection Act
Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare policies impacting ESRD; Restore Protections for Dialysis Patients Act - H.R.2199/S.1173; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis; Kidney Care Access Protection Act - H.R. 6214/S.2730
Kidney Care Access Protection Act
Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare policies impacting ESRD; Restore Protections for Dialysis Patients Act - H.R.2199/S.1173; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis; Kidney Care Access Protection Act - H.R. 6214/S.2730
Kidney Care Access Protection Act
Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare policies impacting ESRD; Restore Protections for Dialysis Patients Act - H.R.2199/S.1173; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis; Kidney Care Access Protection Act - H.R. 6214/S.2730
Restore Protections for Dialysis Patients Act
Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare policies impacting ESRD; Restore Protections for Dialysis Patients Act - H.R.2199/S.1173; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis; Kidney Care Access Protection Act - H.R. 6214/S.2730
Restore Protections for Dialysis Patients Act
Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare policies impacting ESRD; Restore Protections for Dialysis Patients Act - H.R.2199/S.1173; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis; Kidney Care Access Protection Act - H.R. 6214/S.2730
Restore Protections for Dialysis Patients Act
Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare policies impacting ESRD; Restore Protections for Dialysis Patients Act - H.R.2199/S.1173; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis; Kidney Care Access Protection Act - H.R. 6214/S.2730
Kidney Care Access Protection Act
Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare policies impacting ESRD; Restore Protections for Dialysis Patients Act - H.R.2199/S.1173; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis; Kidney Care Access Protection Act - H.R. 6214/S.2730
Kidney Care Access Protection Act
Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare policies impacting ESRD; Restore Protections for Dialysis Patients Act - H.R.2199/S.1173; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis; Kidney Care Access Protection Act - H.R. 6214/S.2730
Kidney Care Access Protection Act
Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare policies impacting ESRD; Restore Protections for Dialysis Patients Act - H.R.2199/S.1173; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis; Kidney Care Access Protection Act - H.R. 6214/S.2730
Restore Protections for Dialysis Patients Act
Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare policies impacting ESRD; Restore Protections for Dialysis Patients Act - H.R.2199/S.1173; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis
Restore Protections for Dialysis Patients Act
Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare policies impacting ESRD; Restore Protections for Dialysis Patients Act - H.R.2199/S.1173; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis
Restore Protections for Dialysis Patients Act
Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare policies impacting ESRD; Restore Protections for Dialysis Patients Act - H.R.2199/S.1173; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis; Kidney Care Access Protection Act - H.R. 6214/S.2730
Kidney Care Access Protection Act
Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare policies impacting ESRD; Restore Protections for Dialysis Patients Act - H.R.2199/S.1173; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis; Kidney Care Access Protection Act - H.R. 6214/S.2730
Restore Protections for Dialysis Patients Act
Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare policies impacting ESRD; Restore Protections for Dialysis Patients Act - H.R.2199/S.1173; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis; Kidney Care Access Protection Act - H.R. 6214/S.2730
Restore Protections for Dialysis Patients Act
Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare policies impacting ESRD; Restore Protections for Dialysis Patients Act - H.R.2199/S.1173; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis
Restore Protections for Dialysis Patients Act
Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare policies impacting ESRD; Restore Protections for Dialysis Patients Act - H.R.2199/S.1173; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis
Kidney Care Access Protection Act
Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare policies impacting ESRD; Restore Protections for Dialysis Patients Act - H.R.2199/S.1173; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis; Kidney Care Access Protection Act - H.R. 6214/S.2730
Issues related to treatment of autism spectrum disorder
Filing targets: Food & Drug Administration (FDA)
GOSSAMER BIO, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to FDA regulation of pharmaceuticals
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
HCA MANAGEMENT SERVICES, L.P. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to the use of artificial intelligence in health care; Issues related to interoperability; Issues related to Health Data Privacy; Issues related to Health Information Technology
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CARA MEDICAL via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to Medicare reimbursement for medical devices
Issues related to Medicare reimbursement for medical devices
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ARCUTIS BIOTHERAPEUTICS, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to tariffs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FLEX VASCULAR via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues regarding coding and reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HISTOSONICS, INC via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to Medicare coverage of histotripsy procedures
Issues related to Medicare coverage of histotripsy procedures
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PROVERUM MEDICAL via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to medical devices
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CLEARFLOW, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to Medicare inpatient reimbursement for medical devices
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR AFFORDABLE PET CARE via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Educate policymakers about the veterinary medicine landscape
Educate policymakers about the veterinary medicine landscape
Educate policymakers about the veterinary medicine landscape
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MANNKIND CORPORATION via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to Medicare/Medicaid reimbursement
Issues related to Diabetes care
Issues related to the Tricare Program
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GAURDANT HEALTH via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to health screening
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ATARA BIOTHERAPEUTICS, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to regulation of cell therapies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INDEMED via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to the No Surprises Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MAGNOLIA MEDICAL TECHNOLOGIES, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to medical devices
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MAGNUS MEDICAL, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to Medical Device Reimbursement
Issues related to Medical Device Reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COLOPLAST CORP via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to Medicare reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RAYNER INTRAOCULAR LENSES LIMITED via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to Reauthorization of the NO PAIN Act ; Medicare issues related to a non-opioid product
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PAR HEALTH USA, LLC via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to pharmaceutical tariffs
Issues related to domestic pharmaceutical manufacturing; Issues related to supply chain resilience
Filing targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE, U.S. Trade Representative (USTR)
INDIVIOR INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to substance use disorder
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AGIOS PHARMACEUTICALS, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to prescription drugs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NEUSPERA MEDICAL via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENETIX BIOTHERAPEUTICS via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
issues related to FDA regulation of rare disease therapies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OPUS GENETICS, INC via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
issues related to FDA regulation of gene therapies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ATEA PHARMACEUTICALS, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to hepatitis C and prescription drugs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ACME UNITED CORPORATION via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to trade
Issues related to medical products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AVALON HEALTHCARE SOLUTIONS via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
issues related to diagnostic laboratory services
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JCYTE, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to cell therapy development
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE ALLERGY & ASTHMA ALLIANCE via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
issues related to allergy & asthma reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MOBIA MEDICAL, INC (FKA MICROTRANSPONDER) via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to medical devices
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CAPRICOR via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to rare disease therapeutic development
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ONE CALL, CORP via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to the Federal Employees Compensation Act (FECA)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHATHOM PHARMACEUTICALS via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to drug approval
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RECOR MEDICAL via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to coverage of medical devices
Issues related to coverage of medical devices
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SUMMIT BEHAVIORAL HEALTHCARE via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to behavioral healthcare companies and substance use services
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALEXION PHARMACEUTICALS via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Medicare and Medicaid reimbursements for pharmaceuticals
Issues related to pharmaceuticals
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INSMED, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to Medicare reimbursement of pharmaceutical products
General Issues of interest to pharmaceutical companies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HARROW INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to Medicare rebates
Issues related to the regulation of pharmaceuticals
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
KENDAL NUTRICARE LTD via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to formula
Issues related to tariffs
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
BIOTISSUE via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
issues related to tissue products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SPARC via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
issues related to pharmaceutical drugs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NEUROTECH PHARMACEUTICALS via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to approval of combination products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMGEN INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
issues related to pharmaceutical drugs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ILLUMINA, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
NIH Funding
Issues related to health care diagnostics
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WE WORK FOR HEALTH via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to implementation of the Inflation Reduction Act of 2022; Issues relating to Medicare Part B and Medicare Part D drug pricing reforms.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MOMENTOUS via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues Related to Defense and Human Performance
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COLLEGIUM PHARMACEUTICAL via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to pharmaceutical drugs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMING HEALTHCARE, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to FDA and rare diseases
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SUPERNUS PHARMACEUTICALS INC via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
issues related to the pharmaceutical industry
issues related to Medicare drug reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MEDICAL DEVICE MANUFACTURERS ASSOCIATION via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
issues related to medical devices
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANON & CO. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
General Issues of interest to pharmaceutical companies
Medicare reimbursement of pharmaceuticals
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
STERIS CORPORATION via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
medical device manufacturing, servicing, and sterilization issues; FDA modernization
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GILEAD SCIENCES, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to regulation of prescription drugs and biologics
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BROOKDALE SENIOR LIVING INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
issues related to senior health care
issues related to senior housing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CATALYST PHARMACEUTICALS via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
General FDA issues related to orphan drugs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HARMONY BIOSCIENCES, LLC via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to the development and approval of therapies for rare diseases
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORCHARD THERAPEUTICS NORTH AMERICA via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Matters affecting Medicare/Medicaid Issues
Matters affecting Medicare/Medicaid Issues
Matters affecting Medicare/Medicaid Issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ARDELYX, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to medication affordability and access
Issues related to Medicare ESRD benefit and chronic kidney disease management
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENUS LIFESCIENCES via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
issues related to pharmaceutical drugs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TENNESSEE RURAL HEALTH IMPROVEMENT ASSOCIATION (FKN TENNESSEE FARM BR. ASSN.) via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
health care coverage
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
U.S. RENAL CARE via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to Medicare policies impacting ESRD; Restore Protections for Dialysis Patients Act - H.R.2199/S.1173; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis; Kidney Care Access Protection Act - H.R. 6214/S.2730
Filing targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
ACCURAY INCORPORATED via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
issues related to tariffs and trade
Issues related to Medicare payment for/access to radiation therapy services
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE, U.S. Trade Representative (USTR)
BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to diabetes and cardiovascular disease
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GLAUKOS CORPORATION (FKA AVEDRO, INC.) via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
issues related to medical device and drug coverage and reimbursement
H.R. 2527, the Early Detection of Vision Impairments for Children Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TERUMO BCT via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to supply chain constraints
Issues related to apheresis access and reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SSI GROUP via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to health IT and medical records
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LIVANOVA USA INC via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to epilepsy; issues related to telehealth
Medicare beneficiary access to procedures performed in ambulatory surgical centers; Medicare beneficiary access to treatments for depression and epilepsy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
IBA PROTON THERAPY via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · RR
issues related to coverage of proton therapy
issues related to coverage of proton therapy
FLOREO INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · RR
issues related to treatment of autism spectrum disorder
ASTELLAS PHARMA US via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
issues related to pharmaceutical drugs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INNOVAGE via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · 3T
issues related to the PACE program
issues relevant to the PACE program
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HANSA BIOPHARMA AB via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · RR
Issues related to organ transplants; Medicare issues relevant to pharmaceutical companies
Issues related to organ transplants; Medicare issues relevant to pharmaceutical companies
ARTERA INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · RR
Issues related to cancer screening, diagnosis and digital pathology; Medicare reimbursement of laboratory developed tests and software as a medical device
Issues related to cancer screening, diagnosis and digital pathology; Medicare reimbursement of laboratory developed tests and software as a medical device
ARGENTA US HOLDINGS, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · RR
Issues related to animal health
GOSSAMER BIO, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · RR
Issues related to FDA regulation of pharmaceuticals
HCA MANAGEMENT SERVICES, L.P. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · RR
Issues related to the use of artificial intelligence in health care; Issues related to Interoperability; Issues related to Health Data Privacy; Issues related to Health Information Technology
CARA MEDICAL via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · RR
Issues related to Medicare reimbursement for medical devices
Issues related to Medicare reimbursement for medical devices
CLEARFLOW, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · RA
Medicare inpatient reimbursement for medial devices
SKY MARKETING CORPORATION via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · 3T
Issues related to hemp
Issues related to hemp
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NEURALINK CORP. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · 3T
Issues related to the development and commercialization of brain-computer interfaces
Issues related to coverage of medical devices
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ARCUTIS BIOTHERAPEUTICS, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · RR
Issues related to tariffs
HISTOSONICS, INC via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · RR
Issues related to Medicare coverage of histotripsy procedures
Issues related to Medicare coverage of histotripsy procedures
FLEX VASCULAR via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · RR
issues regarding coding and reimbursement
JCYTE, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · RA
Issues related to cell therapy development.
PROVERUM MEDICAL via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · RR
Issues related to medical devices
CLEARFLOW, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · RR
Medicare inpatient reimbursement for medical devices
COALITION FOR AFFORDABLE PET CARE via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · second_quarter · Q2
Educate policymakers about the veterinary medicine landscape
Educate policymakers about the veterinary medicine landscape
Educate policymakers about the veterinary medicine landscape
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NEURALINK CORP. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · second_quarter · Q2
Issues related to the development and commercialization of brain-computer interfaces
Issues related to coverage of medical devices
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MANNKIND CORPORATION via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · second_quarter · Q2
Issues related to the Tricare Program
Issues related to Medicare/Medicaid reimbursement
Issues related to Diabetes care
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GAURDANT HEALTH via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · second_quarter · Q2
Issues related to health screening
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ATARA BIOTHERAPEUTICS, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · second_quarter · Q2
Issues related to regulation of cell therapies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INDEMED via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · second_quarter · Q2
Issues related to the No Surprises Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MAGNOLIA MEDICAL TECHNOLOGIES, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · second_quarter · Q2
Issues related to medical devices
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MAGNUS MEDICAL, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · second_quarter · Q2
Issues related to Medical Device Reimbursement
Issues related to Medical Device Reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COLOPLAST CORP via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · second_quarter · Q2
Issues related to Medicare reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RAYNER INTRAOCULAR LENSES LIMITED via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · second_quarter · Q2
Issues related to Reauthorization of the NO PAIN Act ; Medicare issues related to a non-opioid product
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORCHARD THERAPEUTICS NORTH AMERICA via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · second_quarter · Q2
Matters affecting Medicare/Medicaid Issues
Matters affecting Medicare/Medicaid Issues
Matters affecting Medicare/Medicaid Issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SKY MARKETING CORPORATION via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · second_quarter · Q2
Issues related to hemp
Issues related to hemp
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PAR HEALTH USA, LLC via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · second_quarter · Q2
Issues related to pharmaceutical tariffs
Issues related to domestic pharmaceutical manufacturing; Issues related to supply chain resilience
Filing targets: HOUSE OF REPRESENTATIVES, SENATE